Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03497845 · ClinicalTrials.gov registry record · Phase 2
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
A Phase 2 study, sponsored by Biomedical Advanced Research and Development Authority.
- Completed
- Registry status
- Phase 2
- Development phase
- 720
- Enrollment target
NCT03497845 is a Phase 2 study that has completed, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 720 participants.
The verdict
NCT03497845, a Phase 2 study, has completed, sponsored by Biomedical Advanced Research and Development Authority.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 720 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains. The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.
Interventions
- BIOLOGICAL VN
- BIOLOGICAL IN
- BIOLOGICAL dk/BANG
- BIOLOGICAL gf/WA
- BIOLOGICAL bhg/QL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2019-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03497845
The ClinicalTrials.gov registry entry for NCT03497845 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which VN is the first listed.
NCT03497845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03497845 about?
NCT03497845 is a clinical study titled "Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59". The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains. The study ...
What is the current status of trial NCT03497845?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 720 participants. The study started on 2018-03-15. Estimated completion is 2019-11-19.
What interventions are being tested in trial NCT03497845?
The interventions under investigation include: VN (BIOLOGICAL), IN (BIOLOGICAL), dk/BANG (BIOLOGICAL), gf/WA (BIOLOGICAL), bhg/QL (BIOLOGICAL).
Who is sponsoring clinical trial NCT03497845?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.